ライフサイエンスコーパス: therapeutic benefit

1 NA-binding domain, which may be targeted for therapeutic benefit.

2 enchymal stromal cells (MSCs) with potential therapeutic benefit.

3 the potential for targeting hydroxylases for therapeutic benefit.

4 ence cocaine-associated autophagy may afford therapeutic benefit.

5 ntial approach to modulate Wnt signaling for therapeutic benefit.

6 ing lead compounds to modulate autophagy for therapeutic benefit.

7 ract the initial stages of disease may offer therapeutic benefit.

8 ependency on SIRT2 that can be exploited for therapeutic benefit.

9 higher affinity for their ligands to achieve therapeutic benefit.

10 could address this gap but lack evidence of therapeutic benefit.

11 otumorigenic factors and can be targeted for therapeutic benefit.

12 on non-adherence is a missed opportunity for therapeutic benefit.

13 ets that may be differentially exploited for therapeutic benefit.

14 which could be one mechanism underlying the therapeutic benefit.

15 anding beta-cell mass could have significant therapeutic benefit.

16 anism of circulating inhibitors to achieve a therapeutic benefit.

17 Thus, methods targeting LRV1 could have therapeutic benefit.

18 3 axis in PCa patients has failed to provide therapeutic benefit.

19 ccine immunotherapy, yet resulted in limited therapeutic benefit.

20 erging strategies to target this process for therapeutic benefit.

21 ific CD8(+) T cell responses associated with therapeutic benefit.

22 anced regulatory T cell activity may provide therapeutic benefit.

23 URKA inhibitors has the potential to provide therapeutic benefit.

24 ipulation of mitochondrial dynamics may have therapeutic benefit.

25 application of this approach has had limited therapeutic benefit.

26 blown apoptosis by navitoclax or ABT-199 for therapeutic benefit.

27 o identify existing drugs, which could be of therapeutic benefit.

28 not given prednisolone, which may offset its therapeutic benefit.

29 st leukemia, thereby providing an additional therapeutic benefit.

30 pyruvate transport and metabolism may afford therapeutic benefit.

31 r cell liabilities that can be exploited for therapeutic benefit.

32 NAOXs, for use as functional probes and for therapeutic benefit.

33 optimisation of glycaemic control could have therapeutic benefit.

34 more rapid rituximab clearance have reduced therapeutic benefit.

35 orts to develop DNA demethylating agents for therapeutic benefit.

36 hallenges in translating these findings into therapeutic benefit.

37 ematoma expansion with maximum potential for therapeutic benefit.

38 n and dysregulation that can be targeted for therapeutic benefit.

39 s this that need to be directly targeted for therapeutic benefit.

40 ore mucosal Th17 function may have important therapeutic benefit.

41 potent ER antagonists may be of substantial therapeutic benefit.

42 nction in tumors expressing N131Y could have therapeutic benefit.

43 ulate GABA- and/or glycinergic signaling for therapeutic benefit.

44 ial silencing of mutant transcripts may have therapeutic benefit.

45 a consequence, targeting M-ILK could provide therapeutic benefit.

46 eve that repurposing of NTZ for PD may offer therapeutic benefit.

47 the individual biome predicts likelihood of therapeutic benefit.

48 teins arising from these expanded loci holds therapeutic benefit.

49 tential enzyme inhibitors with regulatory or therapeutic benefit.

50 ow efficacy of cell engraftment still limits therapeutic benefit.

51 the amount of a specific protein might be of therapeutic benefit.

52 ation is thought to be essential for lasting therapeutic benefit.

53 or whether this process can be targeted for therapeutic benefit.

54 ng, antidepressant modality with a prolonged therapeutic benefit.

55 trategies to activate expression may provide therapeutic benefit.

56 y opportunities to control heterogeneity for therapeutic benefit.

57 ants and ideas on how to manipulate them for therapeutic benefit.

58 cing Nemo through gene therapy might provide therapeutic benefits.

59 his system under some conditions might bring therapeutic benefits.

60 c stem/progenitor cell functions may provide therapeutic benefits.

61 target in aging, affording preventative and therapeutic benefits.

62 gesting that targeting this pathway may have therapeutic benefits.

63 eatment is required to generate and maintain therapeutic benefits.

64 proteins such as TopBP1 and Brd4 would have therapeutic benefits.

65 d pathologies and harnessing their potential therapeutic benefits.

66 storing the physiologic gradient may provide therapeutic benefits.

67 ential of these systems to provide sustained therapeutic benefits.

68 promote anti-inflammatory responses and have therapeutic benefits.

69 h CSCs and bulk tumor cells may offer better therapeutic benefits.

70 n of daily buprenorphine while retaining its therapeutic benefits.

71 n the skin by dietary fish oil could provide therapeutic benefits.

72 ve approach to modulate the CB1 receptor for therapeutic benefits.

73 ulating their function or depleting them for therapeutic benefits.

74 ship that could potentially be harnessed for therapeutic benefits.

75 active KP metabolites could underlie several therapeutic benefits.

76 ith BET bromodomain inhibition may offer new therapeutic benefits.

77 , and that interferon antagonists could have therapeutic benefits.

78 Although first-line antidepressants offer therapeutic benefit, about 35% of depressed patients are

79 ion alone results in mild kidney injury, the therapeutic benefit afforded by puerarin in DN remained

80 that neural stem cells may offer significant therapeutic benefit after CNS injury; however, this proc

81 ute lung injury model with the potential for therapeutic benefit against a wide array of injurious ex

82 first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma in a phase III clin

83 tervention also has the potential for direct therapeutic benefits, allowing healthy tissue and networ

84 ociated with improved survival and may offer therapeutic benefit among carefully selected patients.

85 in symptomatic older patients would confer a therapeutic benefit, an important consideration as the m

86 tion load and predicted neoantigen load with therapeutic benefit and (2) determine whether intratumor

87 n stimulation can sometimes yield suboptimal therapeutic benefit and can cause adverse effects.

88 on of low-dose PMO25 in SMA mice can provide therapeutic benefit and phenotypic rescue, presumably vi

89 In order to improve the potential therapeutic benefit and ultimately survival outcomes, we

90 science is important to further enhance the therapeutic benefits and reduce side effects.

91 ation, definition of sustained robustness of therapeutic benefit, and emulation of clinical disease.

92 tivity of RHC variants might be restored for therapeutic benefit are unknown.

93 ivated receptor gamma (PPARgamma), but their therapeutic benefits are compromised by severe side effe

94 e but the neural mechanisms underlying these therapeutic benefits are largely unknown.

95 distinct regimens, despite their respective therapeutic benefit as monotherapy, may together provide

96 (i.e., cetuximab) does not provide long-term therapeutic benefit as standalone treatment.

97 inhibition via exogenous agents may provide therapeutic benefit, as has long been proposed.

98 function and may explain the angiogenic and therapeutic benefits associated with CD34(+) stem cell t

99 tient-derived models to assess the potential therapeutic benefits associated with intracranial 2-HG i

100 y or a neutrophil-depleting antibody yielded therapeutic benefits associated with reduced neutrophil

101 Considering the potential therapeutic benefit attainable through modulation of the

102 mediator biosynthesis, resulted in a loss of therapeutic benefit bestowed on mesenchymal stromal cell

103 n neovascular AMD subjects did not result in therapeutic benefit beyond that obtained with ranibizuma

104 ted to reverse immunosuppression and augment therapeutic benefits beyond tumoricidal effects to harne

105 ary, lamotrigine was associated with limited therapeutic benefit but not harm; lithium with both bene

106 he BRAF V600E inhibitor vemurafenib provides therapeutic benefits but the common emergence of drug re

107 ss-of-function MC1R in MC1R RHC variants for therapeutic benefit by activating MC1R protein palmitoyl

108 alter thymic output and potentially provide therapeutic benefit by enhancing anti-tumor immunity.

109 nt with previous findings that TM may have a therapeutic benefit by inhibiting EGFR activation.

110 dynamics and RV performance, and might offer therapeutic benefit by modifying fundamental pathophysio

111 d or acquired arrhythmia syndrome may confer therapeutic benefit by reducing the incidence of trigger

112 ly with NK cell-based therapies may heighten therapeutic benefits by augmenting NK cell-mediated anti

113 DP-ribosylation, and we anticipate potential therapeutic benefits by targeting this enzyme-enzyme TA

114 d during pre-symptomatic stages, significant therapeutic benefit can still be achieved after the onse

115 The fleeting nature of ketamine's therapeutic benefit, coupled with its potential for abus

116 To maximize therapeutic benefit, drug combinations and schedules mus

117 ory and that targeting GABA(B)Rs may provide therapeutic benefit for age-related impairments in execu

118 ors, and targeting these cells might provide therapeutic benefit for cancer patients.

119 Targeting of NFIL3 could be of therapeutic benefit for cancer patients.

120 during absence seizures, and their potential therapeutic benefit for controlling other types of gener

121 inery, including RNR, has been exploited for therapeutic benefit for decades and remains an important

122 f renal RAS activity, suggesting a potential therapeutic benefit for kidney function.

123 ation of the GDNF pathway may have potential therapeutic benefit for management of radiation-induced

124 "superkine" called H9) provided substantial therapeutic benefit for mice specifically bearing MHC cl

125 s, such as the rapalogs, would provide clear therapeutic benefit for patients at high risk of develop

126 Targeting of this pathway may have therapeutic benefit for patients with sepsis or other se

127 dependent adaptive immune response may be of therapeutic benefit for PD patients.

128 rginase 1 deficiency and therefore may be of therapeutic benefit for the neurological disabilities in

129 lient protein and HSP90 inhibitors may exert therapeutic benefits for ATL and HAM/TSP patients.

130 Thus, BTA-EG4 may provide broad therapeutic benefits for improving neuronal and cognitiv

131 ssues could ultimately have prophylactic and therapeutic benefits for protection against tularemia.

132 modulation of chaperone function could have therapeutic benefits for the large and growing family of

133 r, these findings suggest that OXR1 may have therapeutic benefits for the treatment of ALS and relate

134 t that targeting Gq/TRPC6 signaling may have therapeutic benefits for the treatment of glomerular dis

135 irected towards the HE4 protein demonstrates therapeutic benefits for the treatment of ovarian cancer

136 ecent epidemiologic studies have suggested a therapeutic benefit from aspirin intake in cancers harbo

137 ty of targeting PPIs and emphasize potential therapeutic benefit from blocking PPIs in hematologic ma

138 Despite this, the current evidence of therapeutic benefit from extended oxytocin treatment rem

139 f our approach is to maximize the chance for therapeutic benefit from the immunotherapy while minimiz

140 r subtypes it has been difficult to separate therapeutic benefit from undesirable side effects.

141 ng in tumors is essential to achieve maximal therapeutic benefit from WNT inhibitory compounds.

142 modulation of hypoxic injury mechanisms for therapeutic benefit has not been achieved, suggesting th

143 mprehension of the mechanisms underlying its therapeutic benefit has remained a major challenge.

144 rts to target mutant Ras in human cancers to therapeutic benefit have also been largely unsuccessful.

145 elective targeting of their function confers therapeutic benefit in a number of diseases.

146 AC1903 also provided therapeutic benefit in a rat model of hypertensive prote

147 nment, and the immune system, with resultant therapeutic benefit in a stringent glioblastoma model.

148 lective inflammasome blockers with potential therapeutic benefit in a wide range of human diseases.

149 metrexed with GMX1777 produced a synergistic therapeutic benefit in A549 and H1299 NSCLC cells in vit

150 aptic and cognitive functions, and may be of therapeutic benefit in AD and other cognitive disorders.

151 ary to effectively modulate this pathway for therapeutic benefit in AD, as CRFR1 antagonists increase

152 that inhibiting ADAM 10 activity could be of therapeutic benefit in AKI.

153 Interference with Rab18 may have significant therapeutic benefit in ameliorating liver fibrosis.

154 ort the notion that asparaginase may offer a therapeutic benefit in AML-not from its well-known enzym

155 nflammation and have been shown to provide a therapeutic benefit in animal models of Parkinson diseas

156 re intestinal immune homeostasis and exert a therapeutic benefit in CeD, and potentially other inflam

157 rs such as palbociclib are likely to provide therapeutic benefit in combination with BRAF inhibitors

158 sis and fatty acidbeta-oxidation and provide therapeutic benefit in diseases associated with mitochon

159 ility to manipulate their function may be of therapeutic benefit in diverse disease conditions.

160 Tau reduction may be of therapeutic benefit in Dravet syndrome and other intract

161 survival, as well as reported to demonstrate therapeutic benefit in HD animal models.

162 can effectively reduce alpha-syn and provide therapeutic benefit in human midbrain neurons.

163 his study, we tested whether this effect had therapeutic benefit in improving protection against path

164 t TCN-032 may provide immediate immunity and therapeutic benefit in influenza A infection, with no ap

165 terest in targeting the Hedgehog pathway for therapeutic benefit in medulloblastoma, particularly giv

166 Drugs that inhibit the MAPK pathway have therapeutic benefit in melanoma, but responses vary betw

167 he use of transplanted astrocytes to produce therapeutic benefit in mouse models of HD.

168 rmacologic inhibition of ROR-gammat provided therapeutic benefit in mouse models of intestinal inflam

169 cologic targeting of ALK1 provided long-term therapeutic benefit in mouse models of mammary carcinoma

170 ce mediated silencing of ATXN1 mRNA provides therapeutic benefit in mouse models of the disease.

171 t manipulating complement system may produce therapeutic benefit in muscle injury and regeneration.

172 ed at enhancing vesicular capacity may be of therapeutic benefit in Parkinson disease.

173 uggest that blockade of C5aR/CD88 might have therapeutic benefit in patients with ANCA-associated vas

174 elial factors, such as IL-33, have potential therapeutic benefit in patients with CRS, although the e

175 ed on CLL cells, promise to have significant therapeutic benefit in patients with this disease.

176 le intervention (MEK-inhibition) could be of therapeutic benefit in preventing invasive migration and

177 human, this mechanism might be exploited for therapeutic benefit in rescue strategies.

178 uman tumors; this approach provided a modest therapeutic benefit in some patients but no lasting remi

179 n followed by T4(+) T cells achieved optimum therapeutic benefit in the absence of significant toxici

180 n early human clinical trials, might provide therapeutic benefit in the mouse FXS model.

181 foamy virus vector can be administered with therapeutic benefit in the SCID-X1 dog, a clinically rel

182 It may however be of therapeutic benefit in the subset of PPOI patients who d

183 vance: A short course of cyclosporine was of therapeutic benefit in the treatment of 2 patients with

184 lation of iron homeostasis with hepcidin has therapeutic benefit in the treatment of AKI.

185 potential symptomatic and disease-modifying therapeutic benefit in the treatment of Alzheimer's dise

186 his membrane tryptase may provide additional therapeutic benefit in the treatment of humans with thes

187 fely penetrated local mucosal tissue and had therapeutic benefit in this DSS model of murine colitis.

188 that suppressing the PAK pathway might be of therapeutic benefit in this type of melanoma.

189 at inhibition of IRAK4 has the potential for therapeutic benefit in treating lupus.

190 lencing and their potential manipulation for therapeutic benefit in treating the beta-hemoglobinopath

191 e activity of adherens junctions could be of therapeutic benefit in vascular ageing.

192 tably lymphedema, and the procedure is of no therapeutic benefit in women without axillary metastases

193 ance, as clozapine is more effective and has therapeutic benefits in a broader range of psychiatric d

194 vide novel protective strategies that confer therapeutic benefits in a mouse model of a severe LSD.

195 bition of the DOT1L/AF10 complex may provide therapeutic benefits in an array of malignancies with ab

196 hat inhibition of LTE4 and of GPR99 may have therapeutic benefits in asthma.

197 targeting of this enzyme may have important therapeutic benefits in disease mechanisms that involve

198 mate receptor 5 (mGluR5) receptor might hold therapeutic benefits in Fragile X syndrome (FXS).

199 suggest that targeting this pathway may have therapeutic benefits in infections with proinflammatory

200 ith checkpoint abrogation" (PPCA)] displayed therapeutic benefits in preclinical disease models of he

201 Anti-VEGF agents also provide therapeutic benefits in proliferative diabetic retinopat

202 cell function and angiogenesis and may have therapeutic benefits in the setting of diabetes.

203 abundance or activity of collectrin may have therapeutic benefits in the treatment of hypertension an

204 cal targeting of the primary cilium may have therapeutic benefits in the treatment of osteoarthritis.

205 gical inhibitors of PARP provide significant therapeutic benefits in various preclinical disease mode

206 d preclinically and clinically and has shown therapeutic benefit, in both early and advanced stage me

207 immunized mice, also resulted in significant therapeutic benefit, including reduced intrahepatic T-ce

208 Patients gained therapeutic benefit irrespective of their illness severi

209 melanomas 1 mm or more in thickness, but its therapeutic benefit is not clear, pending randomized tri

210 s to these treatments, and data suggest that therapeutic benefit is preferentially achieved in patien

211 e mechanism whereby DcpS inhibition leads to therapeutic benefit is unclear.

212 rapy in hypertrophic cardiomyopathy although therapeutic benefit may depend on disease stage.

213 l agents aimed to modulate KCC2 activity for therapeutic benefit might therefore be highly context-sp

214 NRP-1-derived trap effectively mimicked the therapeutic benefits observed in mice lacking NRP-1-expr

215 more specifically, provide evidence for the therapeutic benefit of a brain endothelial-targeted gene

216 This study investigates the safety and therapeutic benefit of a locally administered lentiviral

217 This therefore suggests an added therapeutic benefit of antiviral treatment in HCV infect

218 f decreased prostaglandin D2 release and the therapeutic benefit of aspirin.

219 in select patients because of the potential therapeutic benefit of betaine supplementation.

220 ically, the findings may help to explain the therapeutic benefit of CGRP-mAb in reducing headaches of

221 ransplanted hepatocytes, thus augmenting the therapeutic benefit of clinical hepatocyte transplantati

222 The therapeutic benefit of cps treatment relied on expressio

223 To evaluate the therapeutic benefit of early low-dose corticosteroid in

224 kinase-mediated gene therapy to optimize the therapeutic benefit of HDACI.

225 leukotrienes to aspirin reactions and to the therapeutic benefit of high-dose aspirin therapy.

226 fying enzymes (HMEs), indicating a potential therapeutic benefit of histone deacetylase inhibitors (H

227 providing clinical mechanisms underlying the therapeutic benefit of ivacaftor.

228 Our data confirm the therapeutic benefit of IVIG and IgG Fc in Ab-induced art

229 of a MET kinase inhibitor, we prove that the therapeutic benefit of MET targeting in cancer cells is

230 While a plethora of studies support a therapeutic benefit of Nrf2 activation and ROS inhibitio

231 Our findings show a significant therapeutic benefit of Pn administration and suggest tha

232 These data suggest a therapeutic benefit of pre-existing HIV-specific ADCC an

233 correlated with presence of HE, nor was the therapeutic benefit of ranibizumab on VA affected negati

234 approach opens possibilities to enhance the therapeutic benefit of small-molecule TLR agonist for a

235 This study sought to assess the therapeutic benefit of SNB in a large, nonrandomized pat

236 ed in some studies identifying a significant therapeutic benefit of TACE plus RT for unresectable HCC

237 tochondrial respiration may help enhance the therapeutic benefit of targeted therapies.

238 Preclinical studies have suggested a therapeutic benefit of targeting the Hedgehog (Hh) signa

239 Mechanistic investigations showed that the therapeutic benefit of this treatment derived from neutr

240 ndpoints may facilitate demonstration of the therapeutic benefit of VS-5584.

241 adoptive cell therapy and may limit expected therapeutic benefits of adoptive cell therapy.

242 Therapeutic benefits of anti-NPCT were also associated w

243 ese links will help us harness the potential therapeutic benefits of autophagy in combating age-relat

244 The possible therapeutic benefits of B-cell depletion in combating tu

245 ne-compromised zebrafish reveal that maximal therapeutic benefits of Bdellovibrio result from the syn

246 e hypocretin responses may contribute to the therapeutic benefits of both rapid acting antidepressant

247 the use of PDE4 inhibitors to potentiate the therapeutic benefits of CFTR correctors and potentiators

248 Further, we propose that the therapeutic benefits of EE could extend to other neurode

249 research is required to assess the potential therapeutic benefits of heart rate reduction.

250 The therapeutic benefits of medicinal plants are well known.

251 We tested the therapeutic benefits of MEK1/2 inhibitors in reversing v

252 e the tissue-level mechanisms underlying the therapeutic benefits of myocardial matrix injection.

253 electively targeting PDE4B should retain the therapeutic benefits of nonselective PDE4 inhibitors.

254 e foundation for future studies to determine therapeutic benefits of polymer-adenovirus combination i

255 omal-autophagic impairment and the potential therapeutic benefits of rapamycin in neuronopathic GD.

256 These findings highlight the very potent therapeutic benefits of Roniciclib in HR-NB through the

257 Therapeutic benefits of siRNA nanotherapy may also apply

258 The therapeutic benefits of the neuraminidase (NA) inhibitor

259 r research is needed to define the potential therapeutic benefits of these alimentary formulations, t

260 ic and experimental rationale, the potential therapeutic benefits of using such compounds to block th

261 The therapeutic benefits of vedolizumab in these patients we

262 Therapeutic benefits offered by tyrosine kinase inhibito

263 mols had a more limited, but still positive, therapeutic benefit on sleep disturbance, anxiety, appet

264 therapy include activating immune system for therapeutic benefit or blockade of immune checkpoints.

265 The therapeutic benefit or detriment of resultant cell hybri

266 The therapeutic benefit or detriment of resultant hybrids is

267 Whether this reflects a therapeutic benefit or is a marker for more favorable un

268 findings challenge the current discussion on therapeutic benefit or risk of IL-6/STAT3 inhibition.

269 ne represents an encouraging opportunity for therapeutic benefits, our experience suggests caution in

270 atory disorders, which may afford additional therapeutic benefit over existing modalities that target

271 46B8 demonstrates a superior therapeutic benefit over Tamiflu and has an additive ant

272 toration of miR-203 expression may provide a therapeutic benefit, particularly in poorly differentiat

273 hological processes underlying its potential therapeutic benefit remain largely unknown.

274 Full and effective use of this target for therapeutic benefit requires a complete understanding of

275 rmation, but harnessing this observation for therapeutic benefit requires an improved understanding o

276 Despite the therapeutic benefit, responses are rarely complete, and

277 n's share of agents that target proteins for therapeutic benefit, there remains no substitute for the

278 A transdermal SARM has a potential to have therapeutic benefit through anabolic activity in muscle

279 pport normal balance behaviors, suggesting a therapeutic benefit to balance with ASO-29 treatment at

280 ation via its coiled-coil domain could be of therapeutic benefit to breast cancer patients by restori

281 pment, it is unclear whether they will be of therapeutic benefit to breast cancer patients, and subse

282 hat strategies to maintain HSP72 may provide therapeutic benefit to enhance mitochondrial quality and

283 all molecule inhibitors of CRTC2 may provide therapeutic benefit to individuals with autoimmune disea

284 xical MAPK pathway activation and to provide therapeutic benefit to patients with RAS mutant cancers,

285 ration-resistant prostate cancer to maximise therapeutic benefit to patients.

286 tin (APN), a pleiotropic adipokine, provides therapeutic benefit to prevent AngII-induced advanced AA

287 t chemical chaperones could be exploited for therapeutic benefit to usher in a new era of personalize

288 terventions to target this pathway may offer therapeutic benefits to prevent or treat lung metastasis

289 ecdin-KO pups, and that fluoxetine may offer therapeutic benefits to PWS patients with respiratory co

290 apy due to its promise in providing superior therapeutic benefits to the current drug combination the

291 tion and refinement of natural products with therapeutic benefit, to the systematic screening of mole

292 residual C5 activity may derogate the drug's therapeutic benefit under certain conditions.

293 The therapeutic benefit was mediated through a reduction in

294 table doses of tetrabenazine that provided a therapeutic benefit were switched overnight to deutetrab

295 Such therapeutic benefits were associated with suppression of

296 arbon monoxide ex vivo would promote further therapeutic benefit when cells are administered in vivo

297 rance mechanisms may drive disease-modifying therapeutic benefit with BACE1 inhibition in AD.

298 The maximal therapeutic benefits with respect to the efficiency of e

299 lipid form (krill oil) may confer additional therapeutic benefit, with improvements in DED symptoms a

300 l means to alter physiological responses for therapeutic benefit, yet the structural bases of modulat